Dynamic Advisor Solutions LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 29.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,758 shares of the company's stock after purchasing an additional 6,920 shares during the period. Dynamic Advisor Solutions LLC's holdings in Novo Nordisk A/S were worth $2,123,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Hawaiian Bank raised its stake in shares of Novo Nordisk A/S by 0.6% in the 1st quarter. First Hawaiian Bank now owns 22,401 shares of the company's stock valued at $1,556,000 after buying an additional 142 shares in the last quarter. Anchor Investment Management LLC raised its position in Novo Nordisk A/S by 1.1% in the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company's stock worth $944,000 after purchasing an additional 150 shares in the last quarter. Xponance Inc. lifted its stake in Novo Nordisk A/S by 5.0% during the first quarter. Xponance Inc. now owns 3,314 shares of the company's stock worth $230,000 after purchasing an additional 158 shares during the period. Foster Dykema Cabot & Partners LLC boosted its holdings in Novo Nordisk A/S by 3.8% during the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock valued at $319,000 after purchasing an additional 166 shares in the last quarter. Finally, 180 Wealth Advisors LLC grew its stake in shares of Novo Nordisk A/S by 3.6% in the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock valued at $348,000 after purchasing an additional 173 shares during the period. 11.54% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
NVO has been the topic of several recent analyst reports. UBS Group lowered Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Zacks Research downgraded shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 20th. Rothschild Redb raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 16th. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a report on Tuesday, September 16th. Finally, Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus price target of $81.00.
Get Our Latest Stock Report on NVO
Novo Nordisk A/S Price Performance
Shares of Novo Nordisk A/S stock traded down $0.70 during trading on Monday, reaching $60.70. The company's stock had a trading volume of 10,729,184 shares, compared to its average volume of 13,091,512. The stock has a 50-day moving average price of $56.71 and a two-hundred day moving average price of $64.92. The stock has a market capitalization of $271.03 billion, a P/E ratio of 16.68, a price-to-earnings-growth ratio of 2.33 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $127.61.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.
Novo Nordisk A/S Cuts Dividend
The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
See Also
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
